The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines

Abstract excerpt

Cisplatin is used to treat a variety of malignancies, including testicular germ cell tumours (TGCTs). Although cisplatin-based chemotherapy yields high response rates, a subset of patients develop cisplatin resistance, limiting treatment options and worsening prognosis. Therefore, there is a high clinical need for new therapeutic strategies targeting cisplatin-resistant TGCTs. MicroRNA-371a-3p (miR-371), the new...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Sarcoma Diagnosis and Treatment
• Share to Sperm and Testicular Function
• Share to Testicular diseases and treatments